Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients
NCT05232370Phase 2Completed
- Sponsor
- Unidad de Investigación Médica en Enfermedades Renales
- Start
- Jan 2022
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enalapril and losartan in oxidative stress (3 arms), sponsored by Unidad de Investigación Médica en Enfermedades Renales. Primary endpoints: Products of lipoperoxidation at 1 year and Nitric Oxide at 1 year. Started Jan 2022; status: completed.
02
Drugs
enalaprillosartan
03
Conditions
oxidative stress
Beyond the preview
Go deeper on NCT05232370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232370.